NMN (nicotinamide mononucleotide) evidence, 2021
Yoshino M, Yoshino J, Kayser BD, et al., Science, 2021 — small RCT of 250 mg/day NMN in postmenopausal women
- Grade
- Design
- rct
- Year
- 2021
- Participants
- 25
- Ingredient
- NMN (nicotinamide mononucleotide)
- Goal
- Heart & metabolic
Effect
One measure of muscle insulin sensitivity improved with NMN; most other metabolic endpoints did not change over 10 weeks.
Limitations and notes
Editorial reference only — NMN is not recommendable on Livestack (regulatory status, SPEC §0.2).